Previous reviews have elucidated the abnormal secretion of IL-18 and IL-1β due to activation of NLPR3 inflammasome, significantly increasing disease severity and lymphoma risk in pSS patients.[21,36] Further studies also should focus on the downstream regulation mechanisms of inflammation after IL-18 activation. This evidence concerns the gene IL18 and lymphoma.